Clinical Profile and Outcome of Large-Vessel Giant Cell Arteritis in Japanese Patients: A Single-Center Retrospective Cohort Study.

OBJECTIVES Recent advances in imaging revealed that giant cell arteritis (GCA) is frequently associated with large vessel involvement (LVI), but they may also contribute to earlier diagnosis and treatment of LV-GCA. We aimed to compare clinical characteristics of GCA with or without LVI and evaluate its association with clinical outcomes. METHOD We retrospectively reviewed the medical records of 36 patients with GCA in Kyoto University Hospital. RESULTS Eighteen patients each were assigned to the LVI(+) and LVI(-) groups. Five-year survival rates in the LVI(+) group was better than in the LVI(-) group (P = 0.034), while five-year relapse-free survival rates were similar between the groups (P = 0.75). The LVI(+) group required lower doses of glucocorticoid at month 6 (P = 0.036). Disease activity evaluated with the Birmingham Vasculitis Activity Score at disease onset was higher in the LVI(-) group (P = 0.014), and the Vasculitis Damage Index score examined at the last visit was higher in the LVI(-) group (P = 0.011). CONCLUSION GCA without LVI had more active disease, severer vascular damage, and worse survival, possibly because of ophthalmic complications and their greater glucocorticoid requirement. Our results revisit the impact of cranial manifestations on disease severity and morbidity.

• Publication year

  2022

• Venue

  Modern Rheumatology

• Publication date

  2022-02-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/mr/roac013PMID 35141755
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comment on: Different treatment options for Takayasu arteritis patients with moderate-to-severe aortic regurgitation: long-term outcomes.

  2021cited by this paper
• Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions

  2020cited by this paper
• Cellular Signaling Pathways in Medium and Large Vessel Vasculitis

  2020cited by this paper
• Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis—Similarities and Differences

  2020cited by this paper
• Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis.

  2019cited by this paper
• Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients.

  2018cited by this paper
• Evaluation of damage in giant cell arteritis

  2018cited by this paper
• Large-vessel giant cell arteritis: diagnosis, monitoring and management

  2018cited by this paper
• Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016

  2017cited by this paper
• Giant-Cell Arteritis: Do We Treat Patients with Large-Vessel Involvement Differently?

  2017cited by this paper
• Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined Arteritis Damage Score, CARDS).

  2017cited by this paper
• A novel susceptibility locus for Takayasu arteritis in the IL12B region can be a genetic marker of disease severity

  2016cited by this paper
• Retrospective analysis of 95 patients with large vessel vasculitis: a single center experience

  2016cited by this paper
• The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis

  2016cited by this paper
• Revisited HLA and non-HLA genetics of Takayasu arteritis—where are we?

  2015cited by this paper
• Large-vessel giant cell arteritis: a cohort study.

  2015cited by this paper
• Childhood-onset Takayasu Arteritis — Experience from a Tertiary Care Center in South India

  2014cited by this paper
• Immune mechanisms in medium and large-vessel vasculitis

  2013cited by this paper
• 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

  2013cited by this paper
• Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation)

  2013cited by this paper
• Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010).

  2013cited by this paper
• Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population.

  2013cited by this paper
• Giant Cell Arteritis with or without Aortitis at Diagnosis. A Retrospective Study of 22 Patients with Longterm Followup

  2012cited by this paper
• Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis

  2012cited by this paper
• The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.

  2010cited by this paper
• Modification and validation of the Birmingham Vasculitis Activity Score (version 3)

  2008cited by this paper
• Prognosis of large-vessel giant cell arteritis.

  2008cited by this paper
• Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years.

  2003cited by this paper
• Disease pattern in cranial and large-vessel giant cell arteritis.

  1999cited by this paper
• Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

  1997cited by this paper

• Clinical Profile of Giant Cell Arteritis and Polymyalgia Rheumatica in a Tertiary Care Hospital in South India

  2026cites this paper
• Performance of Diagnostic Examinations for Giant Cell Arteritis and Subtypes: A Multicenter Japanese Study

  2025cites this paper
• Identification of the VLDLR locus associated with giant cell arteritis and the possible causal role of low-density lipoprotein cholesterol in its pathogenesis.

  2024cites this paper
• Clinical characteristics and courses of Korean patients with giant cell arteritis: a multi-center retrospective study

  2024cites this paper
• Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force

  2023cites this paper
• Demographic characteristics of patients with giant cell arteritis in Sheffield, England

  2023cites this paper
• Biases in Large Vessel Vasculitis.

  2023cites this paper
• Clinical Features and Outcomes of Japanese Patients with Giant Cell Arteritis: A Comparison with Takayasu Arteritis

  2023cites this paper
• Response to: 'Biases in Large Vessel Vasculitis' by Mukhtyar.

  2023cites this paper
• Aging-Related Vascular Inflammation: Giant Cell Arteritis and Neurological Disorders

  2022cites this paper